NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
CITANEST FORTE (epinephrine bitartrate; prilocaine hydrochloride) by AstraZeneca is mechanism of action prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1965.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CITANEST FORTE is a combination local anesthetic injectable containing prilocaine hydrochloride and epinephrine bitartrate. Prilocaine stabilizes neuronal membranes to block pain signal initiation and conduction, while epinephrine provides vasoconstriction to prolong anesthetic effect and reduce systemic absorption. It is indicated for infiltration anesthesia, nerve blocks, and other regional anesthetic procedures.
LOE Approaching
As LOE approaches, commercial teams are likely consolidating; expect reduced headcount and shift toward generic transition strategy.
Mechanism of Action
Mechanism of Action Prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CITANEST FORTE presents limited career growth given its LOE status and minimal linked job openings; roles focus on operational efficiency, cost management, and regulatory compliance rather than innovation or expansion. This assignment suits professionals seeking stable, tactical work in mature product management or those building expertise in generic/post-LOE commercial strategy.
Brand Manager
Worked on CITANEST FORTE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.